DR10624 not checked
Zhejiang Doer Biologics Co., Ltd.
FollowEvery change as it happens, and a Monday email
Trials
4 active
6 in total
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Novel investigational biologic agent for severe hypertriglyceridemia, administered via weekly subcutaneous injection with two titrated dose regimens (low-dose and high-dose) for 64 weeks double-blind treatment period.”In the company’s words, NCT07693777 on ClinicalTrials.gov
- Tested for
- Hypertriglyceridemia (2 trials), Severe Hypertriglyceridemia (sHTG), Severe Hypertriglyceridemia, MASLD
- Main trialPhase 3
- “This is a multicenter, randomized, double-blind, placebo-controlled Phase 3 clinical trial to assess the efficacy and safety of weekly subcutaneous DR10624 injection in adult patients with severe hypertriglyceridemia (sHTG). Eligible participants have persistently elevated fasting triglycerides despite stable background lipid-lowering therapy. Subjects will be randomized at a 2:2:1 ratio to three treatment arms: DR10624 low dose, DR10624 high dose, or matching placebo, receiving weekly subcutaneous injections for a total of 64 weeks double-blind treatment, followed by a 4-week post-treatment…”In the company’s words, NCT07693777 on ClinicalTrials.gov
Other drugs for Hypertriglyceridemia
- OlezarsenIonis Pharmaceuticals, Inc. · Phase 3
- SHR-1918Hengrui · Phase 3
- PlozasiranArrowhead · Phase 3
- MN-001MediciNova · Phase 2
- RBD5044Ribotek Biopharmaceuticals (Shandong) Co., Ltd · Phase 2
- SolbinsiranEli Lilly · Phase 2
Coming up3
- Apr 2028Phase 2 trial completes · ClinicalTrials.gov
- 14 Feb 2029Phase 3 trial completes · ClinicalTrials.gov
- Jun 2030Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials6
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Not yet recruiting | 14 Feb 2029 | A Phase III Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | |
| Phase 3Not yet recruiting | Jun 2030 | A Phase 3 Trial of DR10624 Versus Placebo in Patients With Severe Hypertriglyceridemia | |
| Phase 2Active, not recruiting | 18 Jun 2026 | Phase II Study Evaluating the Efficacy and Safety of DR10624 Injection in MASLD and MetALD Subjects | |
| Phase 2Not yet recruiting | Apr 2028 | A Phase 2 Study to Evaluate the Efficacy and Safety of DR10624 in Subjects With Moderate Hypertriglyceridemia and Diabetic Kidney Disease | |
| Phase 2Completed | 30 Jun 2025 | A Phase II Study to Evaluate the Efficacy and Safety of of DR10624 in Subjects With Severe Hypertriglyceridemia | |
| Phase 1Completed | 10 Oct 2024 | A First in Human (FIH) Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of DR10624 |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026